In April 2025, Ferring Pharmaceuticals announced U.S. Food and Drug Administration ("FDA”) approval of a new manufacturing hub in Parsippany, NJ for Adstiladrin ... Trodelvy In April 2025, Gilead ...

Aubrey Moore netted three goals and had an assist for Parsippany Hills in its 11-9 win over Morris Catholic in Parsippany. Parsippany Hills (2-6) led 6-2 at halftime against Morris Catholic.

Finnian O’Loughlin allowed no hits over five innings with three strikeouts and two walks as top-seeded Delbarton, No. 5 in the NJ.com Top 20, defeated 16th-seeded Parsippany 10-0 in the Morris ...

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform ...

B&G Foods Inc., owner of brands like Green Giant, Ortega and Cream of Wheat, will relocate within Parsippany. The company signed a nearly 16-year lease for a 46,000 square foot space at 8 Sylvan Way.

Gilead Sciences agreed to pay $202 million to the U.S. government and various states to settle civil claims that the drugmaker used speaker programs to pay kickbacks to doctors to induce them to ...

Gilead gave the money to doctors who spoke at HIV Speaker Program events in the form of honoraria payments, meals and travel expenses, according to the U.S. Attorney's Office in Manhattan, which ...

FOSTER CITY, Calif., April 29, 2025--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: BofA ...

Gilead Sciences to Pay $202 Million in US Settlement Over HIV Drug Kickbacks By Jonathan Stempel NEW YORK (Reuters) -Gilead Sciences agreed to pay $202 million to settle a whistleblower lawsuit ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter ...

EPS: US$1.06 (up from US$3.34 loss in 1Q 2024). Our free stock report includes 2 warning signs investors should be aware of before investing in Gilead Sciences. Read for free now. Revenue missed ...

Gilead Sciences(NASDAQ: GILD) didn't have a bad first quarter, but investors didn't find it inspiring either. After publishing its earnings report after market close Thursday, the company saw its ...